StarZero All shows Try the podcast clipper →

Apr 26, 2017 · 21m · 20vc

20VC: 2 Signs That A Company Is Ready For IPO, Why Fund Cycles Are Too Short & Why Management Teams Do Not Want To Go Public with Gene Frantz, General Partner @ CapitalG

Gene Frantz · 12m spoken Harry Stebbings · 8m spoken
0:00 / 0:00

gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions

In this episode of The 20 Minute VC, Harry Stebbings interviews Gene Frantz, General Partner at CapitalG, about the evolution of private equity into growth equity, valuation discipline across market cycles, signs of IPO readiness, and how CapitalG leverages Google's platform to support late-stage founders.

How this conversation actually went

Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Harry holds 40% of the talking time here. How this is scored →

Harry as informed peer 3.0 Guest teaching 3.2 Guest disagreement 1.0 Harry pushing back 2.6
05100:0010:0020:002:41–5:27 · Harry as informed peer 1/10 Gene Frantz's Career Transition from PE to CapitalG Harry sets up an open transition question, allowing Gene to deliver an extended history of private equity's evolution from asset-backed tech hardware into growth equity.5:30–7:46 · Harry as informed peer 3/10 Investing Through Market Cycles & Valuation Discipline Harry prompts Gene on market cycles and contrasts seed-stage 'get on the rocket ship' mindsets with late-stage valuation discipline.7:48–12:16 · Harry as informed peer 3/10 Late-Stage Market Trends & Google's Patient LP Capital Harry probes whether delayed IPOs worry late-stage investors, giving Gene the floor to explain Alphabet's patient capital model and the misaligned incentives of traditional 10-year VC funds.12:17–15:09 · Harry as informed peer 4/10 Differentiating CapitalG in a Commoditized Late-Stage Market Harry challenges Gene on growth equity commoditization, directly raising the industry critique that late-stage VC is often 'merely money'.15:09–19:01 · Harry as informed peer 4/10 Deal Access vs. Selection in Late-Stage VC Harry frames the access versus selection debate and tests Gene in the quickfire section by quoting Rory O'Driscoll on team importance.2:41–5:27 · Guest teaching 4/10 Gene Frantz's Career Transition from PE to CapitalG Harry sets up an open transition question, allowing Gene to deliver an extended history of private equity's evolution from asset-backed tech hardware into growth equity.5:30–7:46 · Guest teaching 2/10 Investing Through Market Cycles & Valuation Discipline Harry prompts Gene on market cycles and contrasts seed-stage 'get on the rocket ship' mindsets with late-stage valuation discipline.7:48–12:16 · Guest teaching 4/10 Late-Stage Market Trends & Google's Patient LP Capital Harry probes whether delayed IPOs worry late-stage investors, giving Gene the floor to explain Alphabet's patient capital model and the misaligned incentives of traditional 10-year VC funds.12:17–15:09 · Guest teaching 3/10 Differentiating CapitalG in a Commoditized Late-Stage Market Harry challenges Gene on growth equity commoditization, directly raising the industry critique that late-stage VC is often 'merely money'.15:09–19:01 · Guest teaching 3/10 Deal Access vs. Selection in Late-Stage VC Harry frames the access versus selection debate and tests Gene in the quickfire section by quoting Rory O'Driscoll on team importance.2:41–5:27 · Guest disagreement 0/10 Gene Frantz's Career Transition from PE to CapitalG Harry sets up an open transition question, allowing Gene to deliver an extended history of private equity's evolution from asset-backed tech hardware into growth equity.5:30–7:46 · Guest disagreement 1/10 Investing Through Market Cycles & Valuation Discipline Harry prompts Gene on market cycles and contrasts seed-stage 'get on the rocket ship' mindsets with late-stage valuation discipline.7:48–12:16 · Guest disagreement 1/10 Late-Stage Market Trends & Google's Patient LP Capital Harry probes whether delayed IPOs worry late-stage investors, giving Gene the floor to explain Alphabet's patient capital model and the misaligned incentives of traditional 10-year VC funds.12:17–15:09 · Guest disagreement 1/10 Differentiating CapitalG in a Commoditized Late-Stage Market Harry challenges Gene on growth equity commoditization, directly raising the industry critique that late-stage VC is often 'merely money'.15:09–19:01 · Guest disagreement 2/10 Deal Access vs. Selection in Late-Stage VC Harry frames the access versus selection debate and tests Gene in the quickfire section by quoting Rory O'Driscoll on team importance.2:41–5:27 · Harry pushing back 0/10 Gene Frantz's Career Transition from PE to CapitalG Harry sets up an open transition question, allowing Gene to deliver an extended history of private equity's evolution from asset-backed tech hardware into growth equity.5:30–7:46 · Harry pushing back 2/10 Investing Through Market Cycles & Valuation Discipline Harry prompts Gene on market cycles and contrasts seed-stage 'get on the rocket ship' mindsets with late-stage valuation discipline.7:48–12:16 · Harry pushing back 3/10 Late-Stage Market Trends & Google's Patient LP Capital Harry probes whether delayed IPOs worry late-stage investors, giving Gene the floor to explain Alphabet's patient capital model and the misaligned incentives of traditional 10-year VC funds.12:17–15:09 · Harry pushing back 5/10 Differentiating CapitalG in a Commoditized Late-Stage Market Harry challenges Gene on growth equity commoditization, directly raising the industry critique that late-stage VC is often 'merely money'.15:09–19:01 · Harry pushing back 3/10 Deal Access vs. Selection in Late-Stage VC Harry frames the access versus selection debate and tests Gene in the quickfire section by quoting Rory O'Driscoll on team importance.

speaking balance: gold is Harry, purple is the guest (3 minute bins)

0:00 · Harry 99.7% · guest 0.3%0:00 · Harry 99.7% · guest 0.3%3:00 · Harry 9.4% · guest 90.6%3:00 · Harry 9.4% · guest 90.6%6:00 · Harry 21.8% · guest 78.2%6:00 · Harry 21.8% · guest 78.2%9:00 · Harry 15.8% · guest 84.2%9:00 · Harry 15.8% · guest 84.2%12:00 · Harry 23.4% · guest 76.6%12:00 · Harry 23.4% · guest 76.6%15:00 · Harry 29% · guest 71%15:00 · Harry 29% · guest 71%18:00 · Harry 78.3% · guest 21.7%18:00 · Harry 78.3% · guest 21.7%21:00 · Harry 100% · guest 0%21:00 · Harry 100% · guest 0%
Sharpest disagreement ▶ 18:00 Gene rejects Rory O'Driscoll's premise on team vs market

When presented with Rory O'Driscoll's claim that market outcomes outweigh team quality at the late stage, Gene firmly disagrees, declaring that team remains crucial in competitive markets.

 Hardest push from Harry ▶ 13:37 Harry confronts growth VC as being 'merely money'

Harry directly challenges Gene with the common industry criticism that late-stage funding offers little differentiation beyond capital, pushing Gene to prove CapitalG's strategic value.

 Biggest teaching moment ▶ 9:51 Gene explains structural VC fund cycle pressures

Gene articulates how standard three-to-five-year fundraising clocks create artificial pressure on portfolio companies to seek liquidity regardless of business maturity.

 Harry holds his own ▶ 18:00 Harry leverages industry quote to challenge guest

Harry demonstrates domain expertise by introducing Rory O'Driscoll's thesis that market drives outcomes over team, forcing Gene to defend his core investment thesis.
the scores for every segment, with the reasoning behind each
ChapterTopicHarry as informed peerGuest teachingGuest disagreementHarry pushing backWhy
Gene Frantz's Career Transition from PE to CapitalG 1400 Harry sets up an open transition question, allowing Gene to deliver an extended history of private equity's evolution from asset-backed tech hardware into growth equity.
Investing Through Market Cycles & Valuation Discipline 3212 Harry prompts Gene on market cycles and contrasts seed-stage 'get on the rocket ship' mindsets with late-stage valuation discipline.
Late-Stage Market Trends & Google's Patient LP Capital 3413 Harry probes whether delayed IPOs worry late-stage investors, giving Gene the floor to explain Alphabet's patient capital model and the misaligned incentives of traditional 10-year VC funds.
Differentiating CapitalG in a Commoditized Late-Stage Market 4315 Harry challenges Gene on growth equity commoditization, directly raising the industry critique that late-stage VC is often 'merely money'.
Deal Access vs. Selection in Late-Stage VC 4323 Harry frames the access versus selection debate and tests Gene in the quickfire section by quoting Rory O'Driscoll on team importance.

Statements from this episode (8)

Opinion
Frantz: Backing high-quality tech companies requires paying full market price
“And for the record, to be involved with any high quality company, you will be paying a full price in the market that we live in today.”
Gene Frantz Apr 26, 2017 ▶ 7:20
Insight
Frantz: Growth investors must enforce valuation limits to generate strong returns
“And so I think selecting a high quality company is absolutely the most important first step, but I think you need to have limits on how much you're willing to pay for that as you think about making money over the longterm and sort of how your returns will come…”
Gene Frantz Apr 26, 2017 ▶ 7:32
Assertion Supported
Frantz: Late-stage private liquidity allows companies to delay going public
“To go public, I would say, you know, it seems like companies need to be a bit larger and a bit more developed than would have been the case 20 years ago. But I think a great deal of the consideration whether they go public Is driven by management teams who may…”
Gene Frantz Apr 26, 2017 ▶ 8:00
Disclosure
Frantz: Alphabet's patient capital allows CapitalG to avoid IPO timeline pressure
“We have in our LP here at Google, Alphabet, the ultimate and very patient capital. And so, if we can find companies to invest in that we can be in for a very long period of time, That are growing and doing the things that they want to be doing and building val…”
Gene Frantz Apr 26, 2017 ▶ 8:50
Insight
Frantz: Short VC fund cycles force artificial liquidity pressure on startups
“And even though funds are ten-year funds, which sounds like a long time, you know, the average investment period for most Funds is probably, you know, three to five years, and so what that means is that every three to four to five years, you've got funds out r…”
Gene Frantz Apr 26, 2017 ▶ 9:54
Insight
Frantz: Business predictability is the most critical requirement for an IPO
“That's right. In terms of predictable results where, you know, the management team has, the business is mature enough where it lends itself to not perfect predictability because of course that doesn't exist, but at least having a Good sense for the cadence of …”
Gene Frantz Apr 26, 2017 ▶ 11:40
Opinion
Frantz: Growth and private equity have become highly commoditized since 2007
“So I would say that investing writ large across growth equity, private equity, has commoditized To a very high degree over the last decade in a way that would not have been the case in the prior 10 years to that.”
Gene Frantz Apr 26, 2017 ▶ 12:39
Disclosure
Frantz: Stripe is a revolutionary payments company with extraordinary traction
“I think our most recent public investment, most recent investment in a private company that, that, that's been publicly disclosed is Stripe, which is a revolutionary company in the payment space with an extraordinary team and traction that's quite unlike what …”
Gene Frantz Apr 26, 2017 ▶ 18:26
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 1,200 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.

Try the podcast clipper Learn more